10-Q: Syndax Reports Strong Product Revenue Growth, Widens Loss

Syndax Pharmaceuticals reported significant revenue growth from its newly launched cancer therapies, Revuforj and Niktimvo, in Q2 2025, though net losses increased due to higher operating expenses.

Summary

• Total revenues for the six months ended June 30, 2025, surged to $57.75 million, up from $3.5 million in the same period of 2024, driven by new product sales.
• Product revenue from Revuforj reached $28.6 million in Q2 2025, a 43% increase over Q1 2025, and $48.64 million for the six months ended June 30, 2025.
• Collaboration revenue from Niktimvo was $9.4 million in Q2 2025, marking significant growth from $13.6 million in Q1 2025, and $9.11 million for the six months ended June 30, 2025.
• Net loss for the six months ended June 30, 2025, was $156.69 million, an increase from $140.46 million in the prior year period.
• Research and development expenses increased by $18.7 million to $123.86 million for the six months ended June 30, 2025, primarily due to ongoing clinical trials and a $10 million milestone payment for axatilimab.
• Selling, general and administrative expenses rose by $32.8 million to $84.84 million for the six months ended June 30, 2025, driven by commercialization activities and increased headcount.
• Cash, cash equivalents, and shortand long-term investments totaled $517.9 million as of June 30, 2025.
• The company incurred $15.9 million in royalty interest expense for the six months ended June 30, 2025, related to the Royalty Pharma Purchase and Sale Agreement.
• An accumulated deficit of $1.38 billion was reported as of June 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company shows strong commercial traction with its new products and positive clinical trial advancements, the increasing net loss and significant cash burn indicate ongoing financial challenges typical of a growth-stage biotech. The need for future capital raises also weighs on the sentiment.

Positives

• Strong commercial launch and revenue growth for Revuforj, with Q2 2025 net revenue of $28.6 million, a 43% increase over Q1 2025.
• Significant growth in Niktimvo collaboration revenue, reaching $9.4 million in Q2 2025, the first full quarter of its U.S. launch.
• FDA granted Priority Review to the sNDA for Revuforj in R/R mNPM1 AML, with a PDUFA target action date of October 25, 2025.
• Positive clinical data for Revuforj from the AUGMENT-101 trial in R/R mNPM1 AML (ORR 48%, CR/CRh 26%, median OS 23.3 months) and R/R NUP98r AML (ORR 60%).
• Updated data from the BEAT AML trial showed a 67% CR rate and 100% flow-MRD negativity rate for revumenib in newly diagnosed older adults with mNPM1 or KMT2Ar AML.
• Updated data from the SAVE trial showed an ORR of 82% and CR/CRh rate of 48% for revumenib in R/R AML or MPAL.
• Ongoing clinical trials for Revuforj and axatilimab across various indications and treatment landscapes, including Phase 3 trials for both products.
• Appointment of Dr. Nick Botwood as Head of Research and Development and Chief Medical Officer, bringing extensive industry experience.

Negatives

• Net loss increased to $156.69 million for the six months ended June 30, 2025, compared to $140.46 million in the prior year period.
• Accumulated deficit grew to $1.38 billion as of June 30, 2025, indicating continued unprofitability since inception (except for 2021).
• Increased operating expenses, with R&D up by $18.7 million and SG&A up by $32.8 million for the six months ended June 30, 2025.
• Cash, cash equivalents, and investments decreased from $724.82 million at December 31, 2024, to $517.86 million at June 30, 2025.
• Net cash used in operating activities increased to $182.96 million for the six months ended June 30, 2025, from $155.19 million in the prior year period.

Risks

• Uncertainty in revenue generation from Revuforj and Niktimvo.
• Challenges in obtaining regulatory approval for additional indications for approved products.
• Potential for delays or problems in product supply, loss of single-source suppliers, or failure to comply with manufacturing regulations.
• Difficulties in identifying, acquiring, or in-licensing additional products or product candidates.
• Inherent uncertainty of clinical success in pharmaceutical product development.
• Challenges in protecting and enhancing intellectual property rights.
• Risks associated with complying with applicable regulatory requirements.
• Adverse impact of unfavorable interest rates, geopolitical unrest, and economic uncertainty on operations and capital markets.
• Potential for increased operating costs due to inflation, supply chain constraints, and wage increases.
• Reliance on future equity offerings, debt financings, and collaboration arrangements to fund future cash needs.

Future Outlook

The company anticipates continued significant research and development and other expenses as it advances its product candidates. It expects to finance future cash needs through a combination of equity offerings, debt financings, and additional funding from license and collaboration arrangements. The company believes its current cash, cash equivalents, and investments, combined with expected Revuforj and Niktimvo revenue, are sufficient to fund existing and planned near-term cash requirements. Data from the Revumenib trial in metastatic MSS colorectal cancer is expected by the end of 2025, and topline data from the MAXPIRe trial in IPF is anticipated in the second half of 2026.

Management Comments

• "We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved products, Revuforj (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate of clinical development programs."
• "We plan to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional therapeutics to expand our pipeline."
• "We believe that the combination of our available cash, cash equivalents, short-term and long-term investments as well as our expected Revuforj gross contribution and Niktimvo collaboration revenue is sufficient to fund existing and planned cash requirements."

Industry Context

Syndax Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on innovative cancer therapies and fibrotic diseases. The successful commercialization of two FDA-approved products, Revuforj and Niktimvo, positions the company as a growing player in the oncology and rare disease markets. The ongoing clinical development programs for additional indications and new disease areas, such as IPF, align with broader industry trends of expanding therapeutic applications for approved drugs and addressing unmet medical needs. The collaboration with Incyte for Niktimvo highlights the increasing prevalence of strategic partnerships in drug development and commercialization to share costs and leverage expertise.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks. However, the rapid revenue ramp-up for Revuforj and Niktimvo, both first-in-class therapies, suggests strong initial market acceptance, which is a positive indicator for novel oncology and rare disease treatments.
• The high R&D and SG&A expenses, coupled with continued net losses and significant cash burn, are typical for a commercial-stage biopharmaceutical company investing heavily in pipeline expansion and product launches, aligning with industry norms for companies in this growth phase.

Management Changes

Related Party Transactions

• The company has a collaboration and license agreement with Incyte Corporation for axatilimab, under which they co-commercialize and co-promote axatilimab (Niktimvo) in the United States, sharing profits and losses equally.
• William Meury, a former member of the company's Board of Directors, resigned in June 2025 to become President and Chief Executive Officer and a board member at Incyte, the company's collaboration partner for Niktimvo.

Stakeholder Impact

• **Shareholders**: Experience increased net losses and cash burn, but also significant revenue growth from new product launches and positive clinical trial data, which could drive future value. Potential dilution from future capital raises is a consideration.
• **Employees**: Increased headcount to support commercialization and ongoing R&D activities, indicating job growth and stability.
• **Customers (Patients/Physicians)**: Benefit from the availability of two newly approved cancer therapies, Revuforj and Niktimvo, and the ongoing development of additional indications and new treatments.
• **Creditors (Royalty Pharma)**: Receiving payments based on Niktimvo net sales, with an effective annual interest rate of approximately 9.08% on the financing liability.

Next Steps

• Report data from the Phase 1 trial evaluating revumenib with intensive chemotherapy (7+3) in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients in Q4 2025 to support pivotal dose selection.
• Initiate REVEAL trials in Q4 2025 to evaluate revumenib in combination with standard of care regimens in newly diagnosed acute leukemia patients with mNPM1 or KMT2A-rearranged AML who are fit for intensive chemotherapy.
• Report data from the trial evaluating revumenib in patients with R/R metastatic microsatellite stable (MSS) colorectal cancer (CRC) by the end of 2025.
• Complete enrollment in the MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis (IPF) in Q4 2025.
• Anticipate topline data from the MAXPIRe trial in the second half of 2026.
• Continue to advance ongoing clinical trials for Revuforj and axatilimab across various indications.

Key Dates

Recommendation

While Syndax Pharmaceuticals demonstrates strong commercial execution with its newly launched products, Revuforj and Niktimvo, driving significant revenue growth, the company continues to incur substantial net losses and high cash burn. The increased R&D and SG&A expenses are expected for a commercial-stage biotech with an active pipeline, but the reliance on future capital raises and the existing royalty financing liability introduce financial risk. The positive clinical data and regulatory progress are encouraging, but the path to profitability remains uncertain. A 'hold' recommendation is appropriate, acknowledging the promising product performance and pipeline advancements while recognizing the ongoing financial challenges and the need for continued capital infusion.

Keywords

Biopharmaceutical, Oncology, Cancer therapies, Revuforj, Revumenib, Niktimvo, Axatilimab, Acute leukemia, KMT2A translocation, mNPM1 AML, Chronic graft-versus-host disease, cGVHD, Idiopathic pulmonary fibrosis, IPF, FDA approval, Clinical trials, SEC filing, Financial results, Biotech, Drug development